Alteration of clinical parameters before mortality and prognostic outcomes of pulmonary hypertension in dogs with myxomatous mitral valve disease
Issued Date
2024-01-01
Resource Type
ISSN
22264485
eISSN
22186050
Scopus ID
2-s2.0-85206913627
Journal Title
Open Veterinary Journal
Volume
14
Issue
9
Start Page
2237
End Page
2249
Rights Holder(s)
SCOPUS
Bibliographic Citation
Open Veterinary Journal Vol.14 No.9 (2024) , 2237-2249
Suggested Citation
Channgam P., Sakcamduang W., Chanmongkolpanit K., Kaenchan P., Buayam W., Janhirun Y., Phonarknguen R., Tansakul M., Riengvirodkij N. Alteration of clinical parameters before mortality and prognostic outcomes of pulmonary hypertension in dogs with myxomatous mitral valve disease. Open Veterinary Journal Vol.14 No.9 (2024) , 2237-2249. 2249. doi:10.5455/OVJ.2024.v14.i9.11 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/101770
Title
Alteration of clinical parameters before mortality and prognostic outcomes of pulmonary hypertension in dogs with myxomatous mitral valve disease
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Myxomatous mitral valve degeneration (MMVD) is a prevalent canine heart condition often accompanied by pulmonary hypertension (PH). Echocardiography is a valuable diagnostic tool for MMVD, but its accessibility is limited in small veterinary clinics. Aim: This study aimed to identify clinical parameters and biochemistry and cardiac biomarkers as prognostic indicators for cardiac mortality in MMVD dogs with and without PH. Animals: Ninety-nine MMVD dogs and nineteen normal dogs. Methods: In a five-year longitudinal study, data including clinical and laboratory measurements as well as echocardiographic parameters were collected every 6 months. Dogs were monitored until death or loss to follow-up, and the cause of death was determined when possible. Statistical analysis was performed to identify factors that predicted death. Results: Alterations in body condition score, total protein, fractional shortening percentage, and mean corpuscular volume were predictive of impending cardiac mortality. High blood urea nitrogen-to-creatinine ratio, heart rate, and low hemoglobin levels were associated with an increased risk of death. N-terminal pro-B-type natriuretic peptide was also a significant predictor of cardiac-related mortality, with higher levels indicating increased risk. Moreover, MMVD dogs with PH had a significantly lower survival rate than those with MMVD without PH. However, no significant difference in survival was observed between MMVD stage C and D with PH and MMVD stage C and D without PH groups. Conclusion: These findings provide valuable insights into the monitoring of MMVD progression in dogs using clinical parameters and biomarkers, especially when echocardiography cannot be performed.